These results suggest that the ICOS-ICOSL axis plays an essential role in CTCL pathogenesis, and targeting the ICOS-ICOSL axis could be a viable strategy for treating CTCL. This evidence concerns the gene ICOS and primary cutaneous T-cell non-Hodgkin lymphoma.